Soluble mimics of the cytoplasmic face of the human V1-vascular vasopressin receptor bind arrestin2 and calmodulin

Molecular Pharmacology

Volumn 70, Issue 1, 2006, Pages 249-258

  Wu, Nan ^a   Macion Dazard, Rosemarie ^a   Nithianantham, Stanley ^a   Xu, Zhen ^a,c   Hanson, Susan M ^b   Vishnivetskiy, Sergey A ^b   Gurevich, Vsevolod V ^b   Thibonnier, Marc ^a   Shoham, Menachem ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALMODULIN; MALTOSE BINDING PROTEIN; RETINA S ANTIGEN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR 1 ELEMENTS ON A SOLUBLE SCAFFOLD; VASOPRESSIN V1 RECEPTOR;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOPLASM; ESCHERICHIA COLI; MOLECULAR MIMICRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ARRESTINS; BINDING SITES; BINDING, COMPETITIVE; CALMODULIN; CARRIER PROTEINS; COBALT; HUMANS; IMMUNOBLOTTING; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; PROTEIN BINDING; RECEPTORS, VASOPRESSIN; RECOMBINANT FUSION PROTEINS; SOLUBILITY; SPECTROMETRY, FLUORESCENCE;

EID: 33745284999     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.018804     Document Type: Article

References (41)

1. Berrada K, Plesnicher CL, Luo X, and Thibonnier M (2000) Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation. J Biol Chem 275:27229-27237.
2. + exchanger isoform 1 (NHE1) is a novel member of the calmodulin-binding proteins. Identification and characterization of calmodulin-binding sites. J Biol Chem 269:13703-13709.
3. Carman CV and Benovic JL (1998) G-protein-coupled receptors: turn-ons and turn-offs. Curr Opin Neurobiol 8:335-344.
4. Celver J, Vishnivetskiy SA, Chavkin C, and Gurevich VV (2002) Conservation of the phosphate-sensitive elements in the arrestin family of proteins. J Biol Chem 277:9043-9048.
5. 2+ stores and calmodulin. J Biol Chem 275:36839-36846.
6. Datta A and Stone MJ (2003) Soluble mimics of a chemokine receptor: chemokine binding by receptor elements juxtaposed on a soluble scaffold. Protein Sci 12:2482-2491.
7. Granier S, Terrillon S, Pascal R, Demene H, Bouvier M, Guillon G, and Mendre C (2004) A cyclic peptide mimicking the third intracellular loop of the V2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein. J Biol Chem 279:50904-50914.
8. Gurevich VV and Benovic JL (1993) Visual arrestin interaction with rhodopsin: sequential multisite binding ensures strict selectivity towards light-activated phosphorylated rhodopsin. J Biol Chem 268:11628-11638.
9. Gurevich VV and Benovic JL (1995) Visual arrestin binding to rhodopsin: diverse functional roles of positively charged residues within the phosphorylation-recognition region of arrestin. J Biol Chem 270:6010-6016.
10. Gurevich VV and Benovic JL (1997) Mechanism of phosphorylation- recognition by visual arrestin and the transition of arrestin into a high affinity binding state. Mol Pharmacol 51:161-169.
11. Gurevich VV and Benovic JL (2000) Arrestin: mutagenesis, expression, purification and functional characterization. Methods Enzymol 315:422-437.
12. Gurevich EV, Benovic JL, and Gurevich VV (2004) Arrestin2 expression selectively increases during neural differentiation. J Neurochem 91:1404-1416.
13. Gurevich VV, Dion SB, Onorato JJ, Ptasienski J, Kim CM, Sterne-Marr R, Hosey MM, and Benovic JL (1995) Arrestin interactions with G protein-coupled receptors: direct binding studies with rhodopsin, β2-adrenergic and m2 muscarinic cholinergic receptors. J Biol Chem 270:720-731.
14. Gurevich VV and Gurevich EV (2004) The molecular acrobatics of arrestin activation. Trends Pharmacol Sci 25:59-112.
15. Gurevich VV and Gurevich EV (2006) The structural basis of arrestin-mediated regulation of G protein-coupled receptors. Pharmacol Ther, in press.
16. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM, and Onorato JJ (1997) Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 272:28849-28852.
17. Hanson SM and Gurevich VV (2006) The differential engagement of arrestin surface charges by the various functional forms of the receptor. J Biol Chem 281:3458-3462.
18. Hoffert JD, Chou CL, Fenton RA, and Knepper MA (2005) Calmodulin is required for vasopressin-stimulated increase in cyclic AMP production in inner medullary collecting duct. J Biol Chem 280:13624-13630.
19. Ke A and Wolberger C (2003) Insights into binding cooperativity of MATa1/MATalpha2 from the crystal structure of a MATa1 homeodomain-maltose binding protein chimera. Protein Sci 12:306-312.
20. Krupnick JG, Gurevich VV, Schepers T, Hamm HE, and Benovic JL (1994) Arrestin-rhodopsin interaction. Multi-site binding delineated by peptide inhibition. J Biol Chem 269:3226-3232.
21. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by beta-arrestins. Science (Wash DC) 308:512-517.
22. Li J, Edwards PC, Burghammer M, Villa C, and Schertler GF (2004) Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol 343:1409-1438.
23. Liu J and Wess J (1996) Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family. J Biol Chem 271:8772-8778.
24. Mukherjee S, Palczewski K, Gurevich VV, Benovic JL, Banga JP, and Hunzicker-Dunn M (1999a) A direct role for arrestins in desensitization of luteinizing hormone/choriogonatropin receptor in porcine ovarian follicular membranes. Proc Natl Acad Sci USA 96:493-498.
25. Mukherjee S, Palczewski K, Gurevich VV, and Hunzicker-Dunn M (1999b) β-Arrestin dependent desensitization of luteinizing hormone/ choriogonadotropin receptor is prevented by a synthetic peptide corresponding to the third intracellular loop of the receptor. J Biol Chem 274:12984-12989.
26. Nakamura K, Liu X, and Ascoli M (2000) Seven non-contiguous intracellular residues of the lutropin/choriogonadotropin receptor dictate the rate of agonist-induced internalization and its sensitivity to non-visual arrestins. J Biol Chem 275:241-247.
27. Nickols HH, Shah VN, Chazin WJ, and Limbird LE (2004) Calmodulin interacts with the V2 vasopressin receptor: elimination of binding to the C terminus also eliminates arginine vasopressin-stimulated elevation of intracellular calcium. J Biol Chem 279:46969-46980.
28. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, and Shichida Y (2002) Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci USA 99:5982-5987.
29. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (Wash DC) 289:739-745.
30. Potter RM, Key TA, Gurevich VV, Sklar LA, and Prossnitz ER (2002) Arrestin variants display differential binding characteristics for the phosphorylated N-formyl peptide receptor carboxyl terminus. J Biol Chem 277:8970-8978.
31. Raman D, Osawa S, Gurevich VV, and Weiss ER (2003) The interaction with the cytoplasmic loops of rhodopsin plays a crucial role in arrestin activation and binding. J Neurochem 84:1040-1050.
32. Rosenthal W, Antaramian A, Gilbert S, and Birnbaumer M (1993) Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase. J Biol Chem 268:13030-13033.
33. Thibonnier M (1998) Development and therapeutic indications of orally-active nonpeptide vasopressin receptor antagonists. Expert Opin Investig Drugs 7:729-740.
34. Thibonnier M (2003) Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol 3:683-687.
35. Thibonnier M, Berti-Mattera LN, Dulin N, Conarty DM, and Mattera R (1998a) Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog Brain Res 119:147-161.
36. Thibonnier M, Coles P, Thibonnier A, and Shoham M (2001a) The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 41:175-202.
37. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, and Mattera R (1998b) Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 449:251-276.
38. Thibonnier M, Plesnicher CL, Berrada K, and Berti-Mattera L (2001b) Role of the human V1 vasopressin receptor COOH terminus in internalization and mitogenic signal transduction. Am J Physiol 281:E81-E92.
39. Turner JH, Gelasco AK, and Raymond JR (2004) Calmodulin interacts with the third intracellular loop of the serotonin 5-hydroxytryptamine1A receptor at two distinct sites: putative role in receptor phosphorylation by protein kinase C. J Biol Chem 279:17027-17037.
40. Vishnivetskiy SA, Hosey MM, Benovic JL, and Gurevich VV (2004) Mapping the arrestin-receptor interface. Structural elements responsible for receptor specificity of arrestin proteins. J Biol Chem 279:1262-1268.
41. Vishnivetskiy SA, Schubert C, Climaco GC, Gurevich YV, Velez M-G, and Gurevich VV (2000) An additional phosphate-binding element in arrestin molecule: implications for the mechanism of arrestin activation. J Biol Chem 275:41049-41057.